Neumora Therapeutics NMRA
NASDAQ NMRA
$0.47 +0.01 (+1.37%)
At close: Nov 11, 2026 · 4:00 PM EST

Neumora Therapeutics (NMRA) Net Long-Term Debt Issued (Repaid) (2025)

Updated

Neumora Therapeutics (NMRA) posted Non-Current Debt of $52.91 million for Q2 2026, up 172.0% from $19.45 million a year earlier but down 0.1% from the prior quarter.

Analysis

Neumora Therapeutics (NMRA) Net Long-Term Debt Issued (Repaid) (2025) Analysis & Trends

At the end of FY2025, Neumora Therapeutics' Non-Current Debt came in at $54.53 million.

  • Quarterly Non-Current Debt has run from a low of $19.45 million in Q2 2025 to a high of $54.53 million in Q4 2025 over five years.
  • According to Business Quant data, Non-Current Debt for the three prior quarters was $52.96 million (Q1 2026), $54.53 million (Q4 2025) and $19.56 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net LT Debt (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -1.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 9.98 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.91 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -3.05 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -19.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Neumora Therapeutics 88.31 Mn -529.65 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 38.90 Mn
Sep 30, 2025 -136,000.00
API Access

Neumora Therapeutics Net Long-Term Debt Issued (Repaid) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=NMRA&period=max&api_key=YOUR_API_KEY